Page 138 - Bio Engineering Approaches to Cancer Diagnosis and Treatment
P. 138

136    CHAPTER 6  Laser-assisted cancer treatment




                          Table 6.1  PPT application of gold nanostructures in NIR region.
                          Type    Targeting agent     Results                        Ref
                          GNS     Biological: PEG     (1) Colloidal stability and blood   [11]
                                  Physical: MRI         circulation time increased due to the
                                                        presence of PEG molecules
                                                      (2) Irreversible tissue damage after
                                                        4–6 min of laser irradiation
                                                      (3) Tumor shrinkage
                                  Biological: anti-Her2   (1) Dual imaging and therapy properties   [12]
                                  antibody conjugated   achieved by controlling scattering
                                  PEG                   and absorption features of the GNSs
                                                      (2) Selective destruction of carcinoma
                                                        cells due to the presence of Her2
                                                        antibody
                                  Biological: anti-Her2   (1) Selective tumor cell damage   [13]
                                  nanobody and PEG      occurred in in vivo cell culture
                                                        medium
                                  Cystine conjugated A54   (1) good targeting ability  [14]
                                  peptides            (2) low cytotoxicity to healthy cells
                                  Physical:           (1) Both superparamagnetic and optical  [15]
                                  superparamagnetic iron   properties in one platform which lead
                                  oxide                 to the ability of dual imaging and
                                  Biological: C225      therapy
                                  antibody, PEG       (2) Selective targeting to cancerous
                                                        cells compared with nan-targeted
                                                        nanoparticles in in vivo model
                                                      (3) Selective PTT treatment
                          GNR     Anti-EGFR antibodies,   (1) Selectively targeted cell lines with   [16]
                                  poly(sodium-p-        overexpressed EGFRs
                                  styrenesulfonate)   (2) Malignance cells destroyed in half
                                                        of the power densities needed to kill
                                                        normal cells
                                  PEG                 (1) Targeted photothermal destruction in  [17]
                                                        in vivo model
                                                      (2) Dramatic tumor volume reduction
                                  CD11b antibodies    (1) Efficient and selective cell death in in   [18]
                                                        vitro model
                                  Anti-Toxoplasma gondii   (1) Efficiently targeted and kill parasitic   [19]
                                  antibodies            protozoans
                                  PEG                 (1) Administrating of X-ray scattering   [20]
                                                        properties of GNRs to guide X-ray
                                                        scattering photothermal agent to
                                                        desire side
                                                      (2) Increase the PPT efficiency
                                  Anti-EGFR antibodies,   (1) Polydopamin improve the GNRs   [21]
                                  polydopamin           modification
   133   134   135   136   137   138   139   140   141   142   143